A therapeutic solution for respiratory RNA viruses that corrects the patient’s TLR7-dependent inflammatory response
- Funded by National Health and Medical Research Council (NHMRC)
- Total publications:0 publications
Grant number: GA276591
Grant search
Key facts
Disease
COVID-19Start & end year
20232026Known Financial Commitments (USD)
$975,718.77Funder
National Health and Medical Research Council (NHMRC)Research Location
Australia, IrelandLead Research Institution
RMIT UniversityResearch Priority Alignment
N/A
Research Category
Therapeutics research, development and implementationResearch Subcategory
N/ASpecial Interest Tags
N/AStudy Type
UnspecifiedClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
Not ApplicableVulnerable Population
Not applicableOccupations of Interest
Not applicable
Abstract
Respiratory virus infections such as COVID-19 and influenza cause mild to severe complications in humans, often resulting in patient death. With limitations in current treatments, there is an urgent need for novel therapeutics to combat these and other viruses. We propose a drug strategy that attacks a critical point in the viral pathogenesis process. With the knowledge of this control point, we developed a drug and will evaluate its efficacy for treating COVID-19, influenza and the common cold.